Market capitalization | $28.45m |
Enterprise Value | $23.11m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 12.29 |
P/S ratio (TTM) P/S ratio | 15.13 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 88.13% |
Revenue (TTM) Revenue | $1.88m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a Dare Bioscience, Inc. forecast:
4 Analysts have issued a Dare Bioscience, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1.88 1.88 |
88%
88%
|
|
Gross Profit | 1.84 1.84 |
90%
90%
|
|
EBITDA | -23 -23 |
45%
45%
|
EBIT (Operating Income) EBIT | -23 -23 |
45%
45%
|
Net Profit | -3.60 -3.60 |
91%
91%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Sabrina Johnson |
Employees | 26 |
Founded | 2015 |
Website | www.darebioscience.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.